Literature DB >> 19965943

Progesterone reduces depressive behavior of young ovariectomized, aged progestin receptor knockout, and aged wild type mice in the tail suspension test.

Cheryl A Frye1.   

Abstract

Progestins may have effects to reduce depressive behavior, in part through actions of its metabolite, 5α-pregnan-3α-ol-20-one (3α,5α-THP) at GABA(A) receptors, rather than through intracellular progestin receptors. In this study, we examined the effects of progesterone (10 mg/kg, subcutaneous injection) versus vehicle control (propylene glycol) on the depressive behavior of young and aged mice in the tail suspension test. In Experiment 1, we first characterized progesterone's anti-depressant effects by utilizing young (4-6-month-old) intact or ovariectomized female, and intact or gonadectomized male, C57BL/6 mice. Young female mice showed more depressive behavior than the young male mice. Compared with vehicle administration, progesterone reduced depressive behavior of ovariectomized female, but not male or intact female mice. In Experiment 2, mice were aged (20-24-month-old) intact wild type or progestin receptor knockout mice. Progestin receptor knockout mice showed less depressive behavior than wild type mice. Administration of progesterone to wild type and progestin receptor knockout mice reduced depressive behavior. Together, these data suggest that progesterone can decrease depressive behavior of young adult ovariectomized female, aged wild type and progestin receptor knockout mice. Thus, progesterone's effect to reduce depressive behavior of aged mice may not require actions at the intracellular progestin receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965943      PMCID: PMC3608207          DOI: 10.1177/0269881109349836

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  99 in total

1.  Reference memory, anxiety and estrous cyclicity in C57BL/6NIA mice are affected by age and sex.

Authors:  K M Frick; L A Burlingame; J A Arters; J Berger-Sweeney
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

Review 2.  Diagnosis and treatment of depression in late life. Consensus statement update.

Authors:  B D Lebowitz; J L Pearson; L S Schneider; C F Reynolds; G S Alexopoulos; M L Bruce; Y Conwell; I R Katz; B S Meyers; M F Morrison; J Mossey; G Niederehe; P Parmelee
Journal:  JAMA       Date:  1997-10-08       Impact factor: 56.272

3.  Genotype modulates the aggression-promoting quality of progesterone in pregnant mice.

Authors:  B Svare
Journal:  Horm Behav       Date:  1988-03       Impact factor: 3.587

Review 4.  Neurosteroids and GABAA receptor function.

Authors:  J J Lambert; D Belelli; C Hill-Venning; J A Peters
Journal:  Trends Pharmacol Sci       Date:  1995-09       Impact factor: 14.819

5.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 6.  Clinical uses of antiprogestogens.

Authors:  P F Van Look; H von Hertzen
Journal:  Hum Reprod Update       Date:  1995-01       Impact factor: 15.610

Review 7.  Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy?

Authors:  T B Pearlstein
Journal:  Am J Obstet Gynecol       Date:  1995-08       Impact factor: 8.661

Review 8.  Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.

Authors:  Nikhil D Nihalani; Thomas L Schwartz
Journal:  Curr Opin Investig Drugs       Date:  2007-07

9.  Effects of antidepressant treatment on neuroactive steroids in major depression.

Authors:  E Romeo; A Ströhle; G Spalletta; F di Michele; B Hermann; F Holsboer; A Pasini; R Rupprecht
Journal:  Am J Psychiatry       Date:  1998-07       Impact factor: 18.112

10.  Behavioral action of ethanol in Porsolt's forced swim test: modulation by 3 alpha-hydroxy-5 alpha-pregnan-20-one.

Authors:  K Hirani; R T Khisti; C T Chopde
Journal:  Neuropharmacology       Date:  2002-12       Impact factor: 5.250

View more
  5 in total

Review 1.  Is progesterone a worthy candidate as a novel therapy for traumatic brain injury?

Authors:  Donald G Stein
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

2.  Progesterone treatment shows benefit in a pediatric model of moderate to severe bilateral brain injury.

Authors:  Rastafa I Geddes; Eric A Sribnick; Iqbal Sayeed; Donald G Stein
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

3.  Effects of Estrogen Therapy on the Serotonergic System in an Animal Model of Perimenopause Induced by 4-Vinylcyclohexen Diepoxide (VCD).

Authors:  Nayara Pestana-Oliveira; Bruna Kalil; Cristiane Mota Leite; Ruither Oliveira Gomes Carolino; Lucas Kniess Debarba; Lucila Leico Kagohara Elias; José Antunes-Rodrigues; Janete A Anselmo-Franci
Journal:  eNeuro       Date:  2018-01-22

4.  Considerations of Timing Post-ovariectomy in Mice and Rats in Studying Anxiety- and Depression-Like Behaviors Associated With Surgical Menopause in Women.

Authors:  Juan Francisco Rodríguez-Landa
Journal:  Front Behav Neurosci       Date:  2022-03-04       Impact factor: 3.558

5.  Progesterone Treatment Shows Benefit in Female Rats in a Pediatric Model of Controlled Cortical Impact Injury.

Authors:  Rastafa I Geddes; Bethany L Peterson; Donald G Stein; Iqbal Sayeed
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.